{"title":"Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis.","authors":"C Grote, F Zirkenbach, J N Wagner, M Augustin","doi":"10.1080/09546634.2025.2452987","DOIUrl":"https://doi.org/10.1080/09546634.2025.2452987","url":null,"abstract":"<p><strong>Purpose: </strong>Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.</p><p><strong>Material and methods: </strong>This case report details a 52-year-old female patient with atopic dermatitis treated with dupilumab. After an initially successful treatment, the patient developed a rosacea-like dermatitis. At first, dupilumab was continued alongside doxycycline, metronidazole gel and ivermectin cream.</p><p><strong>Results: </strong>Following a worsening of her skin condition, dupilumab was discontinued. Lebrikizumab was introduced, leading to significant regression of the lesions.</p><p><strong>Conclusions: </strong>This case highlights a rare paradoxical skin reaction to dupilumab, potentially linked to the blockade of IL-4Rα, which may shift the immune response towards a Th1/Th17 phenotype. The findings suggest that alternative therapies, such as IL-13 inhibitors, should be considered when cutaneous side effects arise during dupilumab treatment.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2452987"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ernest H Law, Kent A Hanson, Matthew Harries, Dane Korver, Bintu Sherif, Costel Chirila
{"title":"Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial.","authors":"Ernest H Law, Kent A Hanson, Matthew Harries, Dane Korver, Bintu Sherif, Costel Chirila","doi":"10.1080/09546634.2025.2460577","DOIUrl":"https://doi.org/10.1080/09546634.2025.2460577","url":null,"abstract":"<p><p><b>Purpose:</b> Alopecia areata (AA), an autoimmune disorder characterized by non-scarring hair loss, is detrimental to the psychological health and quality of life of people living with AA. Clinically meaningful hair regrowth is possible, but the relationship with downstream patient-reported outcomes (PROs) is complex.</p><p><p><b>Materials and methods:</b> This post hoc analysis of ALLEGRO-2b/3 (NCT03732807) longitudinal data from Weeks 24-48 compared improvements in PROs between patients who achieved (responders) or did not achieve (non-responders) clinically meaningful scalp hair regrowth. Responders were defined by a Week 24 Severity of Alopecia Tool (SALT) score ≤20 (SALT20) or ≤10 (SALT10). Across 6 PROs assessing multiple AA-related health domains, response proportions and mean changes from baseline were estimated for Weeks 24-48.</p><p><p><b>Results:</b> Among 650 included participants, 114 (17.5%) were SALT20 responders, of which 76 (11.7%) were also SALT10 responders. Generally, more responders than non-responders reported improvements in AA and related symptoms or limitations and satisfaction with hair regrowth. Responders additionally reported greater improvement from baseline than non-responders for measures of AA-related emotional symptoms, mental health, and work or activity limitations.</p><p><p><b>Conclusions:</b> These results support a positive relationship between scalp hair regrowth and downstream PROs-including satisfaction and psychosocial burden-demonstrating an association between clinically meaningful hair regrowth and patient-reported treatment benefits.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2460577"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Junyou Zheng, Zhimin Duan, Beilei Xu, Hao Song, Jianbing Wu, Fang Fang, Nan Sheng, Chengrang Li
{"title":"Hailey-Hailey disease successfully treated with naloxone: 2 case reports and Review of the literature on efficacy of opioid receptor antagonist in Hailey-Hailey disease patients.","authors":"Junyou Zheng, Zhimin Duan, Beilei Xu, Hao Song, Jianbing Wu, Fang Fang, Nan Sheng, Chengrang Li","doi":"10.1080/09546634.2025.2453597","DOIUrl":"https://doi.org/10.1080/09546634.2025.2453597","url":null,"abstract":"<p><strong>Background: </strong>Hailey-Hailey disease (HHD), a genetic blistering disease, is caused by a mutation in a calcium transporter protein in the Golgi apparatus encoded by the <i>ATP2C1</i> gene. Clinically, HHD is characterized by flaccid vesicles, blisters, erosions, fissures, and maceration mainly in intertriginous regions. Some patients remain refractory to conventional treatments. Previously, a series of reports have confirmed naltrexone as an effective option for those patients. However, in China, naltrexone is unavailable in some hospitals and unaffordable for some patients.</p><p><strong>Objective: </strong>To confirm naloxone as a treatment option for HHD, and assess the efficacy rate and safety of naltrexone for patients with HHD.</p><p><strong>Methods: </strong>Two patients with biopsy-proven HHD received naloxone (2 mg/d, <i>via</i> intravenous infusion). We followed up with the two patients, assessing the change of skin lesions and obtaining photographs. We searched the PubMed databases using the keywords 'Hailey-Hailey disease' or 'benign familial pemphigus', and 'naltrexone' or 'naloxone', and reviewed English publications of reports and analyzed the efficacy and safety of naltrexone.</p><p><strong>Results: </strong>Two patients prescribed naloxone showed completely remission in two weeks without any adverse reactions. The total remission rate of naltrexone for HHD is approximately 80%, without severe adverse effects.</p><p><strong>Conclusion: </strong>Naltrexone is effective and safe in the treatment of HHD. Naloxone, an analog of naltrexone, can also effectively and safely treat HHD, potentially offering a new therapeutic option for patients with refractory HHD.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2453597"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143026250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gi-Woong Hong, Sky Wong, Song-Eun Yoon, Jovian Wan, Kyu-Ho Yi
{"title":"Anatomical-based diagnosis and filler injection techniques: marionette line (static labiomandibular fold).","authors":"Gi-Woong Hong, Sky Wong, Song-Eun Yoon, Jovian Wan, Kyu-Ho Yi","doi":"10.1080/09546634.2025.2452954","DOIUrl":"https://doi.org/10.1080/09546634.2025.2452954","url":null,"abstract":"<p><strong>Purpose: </strong>Marionette lines, also known as static labiomandibular folds, are common age-related perioral wrinkles that impact facial aesthetics, particularly in Asian populations. This article aims to examine the anatomical basis, etiology, and filler injection techniques used for treating marionette lines.</p><p><strong>Materials and methods: </strong>The study reviews anatomical studies and clinical practices related to marionette lines. Anatomical observations focus on the position of the modiolus and its relationship to age-related changes. Treatment approaches are examined through a review of filler injection techniques, including supramuscular and submuscular fat layer targeting, as well as neurotoxin use for enhancing treatment outcomes.</p><p><strong>Results: </strong>The review finds that the anatomical positioning of the modiolus in Asian populations predisposes them to increased susceptibility to commissural ptosis and wrinkle formation. Filler injections, particularly using a cannula for deeper layers, are effective for addressing volumetric loss in the supramuscular and submuscular layers. Neurotoxin injections into the depressor anguli oris muscle can enhance results by reducing downward force on the oral commissure.</p><p><strong>Conclusions: </strong>Marionette lines are complex, multifactorial wrinkles that benefit from a multimodal treatment approach, combining dermal fillers and neurotoxins. Awareness of anatomical variations and proper injection techniques is crucial for achieving optimal aesthetic outcomes and minimizing risks.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2452954"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The efficacy of combined phototherapy with topical therapy in vitiligo: a network meta-analysis.","authors":"Liping Luo, Jinhua Huang, Chuhan Fu, Yibo Hu, Jing Chen, Ling Jiang, Qinghai Zeng","doi":"10.1080/09546634.2025.2483808","DOIUrl":"10.1080/09546634.2025.2483808","url":null,"abstract":"<p><strong>Background: </strong>The comparative effects of phototherapy and topical therapy in patients with vitiligo remain unclear. A network meta-analysis (NMA) was conducted to assess which combination therapy was more beneficial for patients with vitiligo.</p><p><strong>Methods: </strong>This study analyzed phototherapy, including narrowband ultraviolet B (NB-UVB) and 308-nm excimer laser/light (EL) combined with topical therapies. Randomized controlled trials were sourced from PubMed, Embase, and Cochrane Library. Data analysis was based on a random-effects model, and surface under the cumulative ranking (SUCRA) curves employed to assess the efficacy of the interventions.</p><p><strong>Results: </strong>This NMA included 27 trials, with a total of 2417 lesions (patches). According to the results of the SUCRA, for achieving ≥50% repigmentation, the top three combination therapies were phototherapy combined with antioxidants (SUCRA 87.7), corticosteroids (SUCRA 69.6), and calcineurin inhibitors (SUCRA 52.5), while for ≥75% repigmentation, the leading therapies were phototherapy combined with antioxidants (SUCRA 89.0), calcineurin inhibitors (SUCRA 70.3), and fractional CO<sub>2</sub> laser (SUCRA 63.6).</p><p><strong>Conclusions: </strong>This meta-analysis suggests that combining phototherapy with topical antioxidants, corticosteroids, or calcineurin inhibitors may offer superior outcomes for vitiligo patients. This study provides a reference for clinicians to develop personalized treatment plans for patients with vitiligo.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2483808"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143805292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The impact of cannabis use on local anesthetic dosing during hair restoration surgery: a case report, proposed mechanisms, and clinical recommendations.","authors":"Aditya K Gupta, Mesbah Talukder, Sharon A Keene","doi":"10.1080/09546634.2025.2482009","DOIUrl":"https://doi.org/10.1080/09546634.2025.2482009","url":null,"abstract":"<p><p>Cannabis use has increased significantly in the last decade. This article presents a case where a patient needed more local anesthetic (LA) than usual to induce effective anesthesia during hair transplant surgery. The reason cannabis users often need more LA is poorly understood. One possibility is that cannabis withdrawal effect makes patients more sensitive to pain and stress. Additionally, vasodilatory property of cannabis may speed up LA clearance from the application site. The interactions of two major cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC), with cannabinoid receptor type 1 (CB1), cannabinoid receptor type 2 (CB2), and transient receptor potential vanilloid 1 (TRPV1) receptors are also complex. Furthermore, CBD and THC function as cytochrome P450 enzyme inhibitors potentially impacting systemic metabolism. When planning to administer LA during hair restoration surgery in cannabis users, clinicians should obtain a detailed history of prior consumption (type of cannabis, frequency, dosage). Preoperative planning should consider the anticipated duration of surgery and calculate the maximum safe LA dose to avoid the risk of toxicity. Also, patients should be carefully monitored for vital signs during surgery. If a patient requires frequent re-injection to remain pain free, the surgeon may need to re-assess the surgical plan to avoid toxicity.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2482009"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hedgehog pathway inhibitors (HHI) combined with radiotherapy and immunotherapy for advanced basal cell carcinoma: a case report.","authors":"Zhuren Ruan, Chen Zhao, Longshan Li, Xianghui Li, Zhijian Yao, Gao Wei","doi":"10.1080/09546634.2025.2462783","DOIUrl":"https://doi.org/10.1080/09546634.2025.2462783","url":null,"abstract":"<p><strong>Purpose: </strong>Basal cell carcinoma (BCC) is one of the most common skin cancers. Most BCCs can be treated with surgery excision. For advanced BCC unsuitable for curative surgery, the combination of radiotherapy and Hedgehog pathway inhibitors (HHI) are effective systemic treatment options. However, there is a scarcity of evidence-based guidelines for the management of patients with advanced or metastatic BCC, particularly those who develop resistance to HHI therapy.</p><p><strong>Materials and methods: </strong>We report the case of a patient with advanced BCC of the head and neck, which originated from a nevus sebaceous.</p><p><strong>Results: </strong>The patient initially responded well to sonidegib, an HHI, but resistance emerged within a month. We then modified the systemic therapy to include a combination of radiotherapy and the anti-PD-1 agent sintilimab.</p><p><strong>Conclusions: </strong>This adjusted treatment regimen led to effective long-term clinical responses without significant adverse events.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2462783"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Low-dose oral minoxidil in a case of short anagen syndrome.","authors":"Divija Sharma, Serena Morsia, Benjamin Ungar","doi":"10.1080/09546634.2025.2460580","DOIUrl":"https://doi.org/10.1080/09546634.2025.2460580","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to explore the effectiveness of low-dose oral minoxidil (LDOM) in treating short anagen hair syndrome (SAS), a rare congenital condition characterized by a shortened anagen phase. While SAS often resolves spontaneously with puberty, treatment remains controversial. Recent studies have demonstrated the efficacy of low-dose oral minoxidil (LDOM) in treating various hair loss conditions, including SAS.</p><p><strong>Materials and methods: </strong>This report presents a case of a 24-year-old female with SAS who experienced significant improvement following LDOM treatment. The patient, who had persistent hair growth issues since childhood, had tried several therapies, including topical 5% minoxidil with limited success. The patient was started on LDOM at 1.25 mg and increased to 2.5 mg after one month.</p><p><strong>Results: </strong>After starting LDOM, the patient reported reduced hair shedding, increased hair length, and improved hair density, which was also confirmed by Canfield's HairMetrix measurements. Despite experiencing mild facial hypertrichosis, the patient opted to continue the treatment.</p><p><strong>Conclusion: </strong>This case adds to the growing body of evidence supporting LDOM as a viable treatment for adult SAS. The findings may also offer insights into the genetic basis of SAS and its overlap with other hair loss conditions, suggesting possible shared therapeutic approaches.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2460580"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abdulmajeed Alosaimi, Abdullah Algarni, Abdulrahman Alharbi, Abdulmalik Alotaibi, Abdullah Alomairi, Mohannad Alsurayhi, Waleed Alharbi
{"title":"Comparative efficacy of minoxidil alone versus minoxidil combined with low-level laser therapy in the treatment of androgenic alopecia: a systematic review and meta-analysis.","authors":"Abdulmajeed Alosaimi, Abdullah Algarni, Abdulrahman Alharbi, Abdulmalik Alotaibi, Abdullah Alomairi, Mohannad Alsurayhi, Waleed Alharbi","doi":"10.1080/09546634.2024.2447355","DOIUrl":"https://doi.org/10.1080/09546634.2024.2447355","url":null,"abstract":"<p><strong>Objective: </strong>This systematic review evaluates the efficacy of minoxidil alone versus minoxidil with low-level laser therapy (LLLT) for androgenic alopecia.</p><p><strong>Study design: </strong>systematic review and meta-analysis.</p><p><strong>Methods: </strong>An online search of PubMed, Web of Science, and MEDLINE was conducted. Randomized clinical trials comparing minoxidil monotherapy with minoxidil and LLLT combination therapy were included based on predefined criteria. The Risk of Bias 2.0 (RoB 2.0) tool was used for quality assessment.</p><p><strong>Results: </strong>From 38 identified studies, 34 remained after excluding 4 duplicates. Further exclusions left 4 eligible studies comparing minoxidil alone with minoxidil and LLLT. The meta-analysis found no statistically significant differences in hair counts between the two groups at baseline, 12 weeks, and 8 weeks post-treatment [mean difference = -0.04, 95% CI -1.22 to 1.14, p = .95, I² = 0%]. Similarly, hair diameter showed no significant differences at the same time points [mean difference = 0.00, 95% CI -0.00 to 0.00, p = .98, I² = 38%].</p><p><strong>Conclusion: </strong>The combination of minoxidil and LLLT does not significantly improve outcomes compared to minoxidil alone for treating androgenic alopecia.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2447355"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lauren N McGrath, Lila G McGrath, John R Edminister
{"title":"A year in review: new treatments and expanded indications in dermatology in 2024.","authors":"Lauren N McGrath, Lila G McGrath, John R Edminister","doi":"10.1080/09546634.2025.2456528","DOIUrl":"https://doi.org/10.1080/09546634.2025.2456528","url":null,"abstract":"<p><strong>Methods: </strong>A literature search was conducted on Drugs@FDA: FDA-Approved Drugs for the year 2024 to identify new dermatologic treatments.</p><p><strong>Results: </strong>In 2024, the FDA approved seven new dermatologic therapies and expanded the indications for seven current therapies. These therapies treat conditions such as atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, molluscum contagiosum, and alopecia areata, among others. Some of these advancements converge dermatology with rheumatology, gastroenterology, and oncology, which continue to transform therapy for patients with multiple diseases.</p><p><strong>Conclusion: </strong>This paper provides a comprehensive overview of these developments and their implications for clinical practice.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2456528"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143054216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}